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Richard E. Champlin,1 Marcos de Lima1Most candidates for hematopoietic stem cell transplantation (HSCT) lack a human leukocyte antigen (HLA)-
identical sibling donor. Some patients may have a related donor with whom they are mismatched at 1 antigen/
allele. It is not knownwhether such amatch is preferable to amatched unrelated donor (MUD).We evaluated
the outcomes (survival, relapse, nonrelapsemortality [NRM]) of all 28 patientswith a singleHLA antigen/allele
mismatch identified through high-resolution HLA typing at HLA-A, -B, -C, -DRB1, and -DQB1, and all 318
patients with myeloid malignancies who received transplants from a 10/10 MUD treated during the same pe-
riod of time at a single institution. Overall, outcomes for patients treated from a 1-antigen/allele mismatch
related donor were significantly worse than from a MUD, primarily because of increased NRM. Overall sur-
vival (OS) rates at 3 years for 1-antigen/allele mismatched related donor andMUD transplant recipients were
19% and 45% (P5 .007), and NRM rates were 40% and 26% (P5 .05), respectively. Patients with class I mis-
matches appeared to have poorer OS than did patients with class II mismatches. A higher incidence of graft
rejectionwas identified in themismatched related donor group (P5.02). These results indicate that transplant
outcomes are better with a MUD than with a 1 antigen/allele-mismatched related donor.
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Most candidates for hematopoietic transplantation
lack a human leukocyte antigen (HLA)-identical sibling
donor. Options for these patients are alternative donor
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6/j.bbmt.2010.10.017a mismatched related donor [1,2]. Some transplant
candidates have a related donor mismatched by only
1 antigen or allele; however, it is uncertain whether
such a donor would be preferable to a MUD.
Several studies have compared the outcomes of
matched related donor (MRD) and MUD transplants
[3-6]. Whereas smaller studies have shown equivalent
outcomes for both donor categories, larger studies
have shown better outcomes with MRD, primarily
related to higher rates of nonrelapse mortality (NRM)
and graft-versus-host disease (GVHD) for recipients
of MUD grafts [7-9]. Many studies have compared
outcomes between related and unrelated donors using
intermediate- and/or high-resolution HLA typing at
3 loci or 4 loci (HLA-A, -B, -C, 6 -DRB1), and the
results emphasize the importance of extending high-
resolution HLA typing to at least 4 HLA loci [10-12].
A few studies have compared transplant outcomes
for patients treated from a 7/8 MRD with 8/8 MUD
(HLA-A, -B, -C, -DRB1) and reported similar923
924 Biol Blood Marrow Transplant 17:923-929, 2011S. O. Ciurea et al.outcomes [13-15]. High-resolution HLA typing is now
routinely performed at 5 loci (HLA-A, -B, -C, -DRB1,
and -DQB1).
We retrospectively analyzed and compared the
outcomes of patients who received transplants from
either a MUD or a 1-antigen/allele mismatched
related donor treated at a single institution.METHODS
Study Population
All patients with myeloid leukemias who had re-
ceived their first hematopoietic transplants from 1
HLA antigen/allele mismatch related donor between
1995 and 2009 were identified in the M.D. Anderson
Cancer Center (MDACC) database. This group was
compared with a cohort of patients who received an
MUD transplant during the same period of time.
All patients had intermediate/high-resolution HLA
typing at all 5 loci either prospectively for those treated
after 2002, or retrospectively if treated before 2002.
All 367 patients with myeloid malignancies identi-
fied were analyzed in this study: 318 received a MUD
(10/10 allele match), and 49 were identified to have
a 1-antigen/allele mismatch related donor transplant
by 4-loci HLA typing (7/8 antigen/allele match). Of
the 49 patients treated with mismatched related
donors, 28 patients (57%) had 1 antigen/allele mis-
matched at HLA class I or II loci (or 9/10), 18 patients
(37%) had 2 alleles mismatched (or 8/10), and 3 pa-
tients (6%) had 3 alleles mismatched (or 7/10). From
the 28 patients with a 1-allele mismatch, 24 had class
I mismatches at either HLA-A or -B locus, and 4 had
class II mismatches at either HLA-DR or -DQ locus.
All patients had provided written informed consent
to undergo hematopoietic stem cell transplantation
(HSCT). A retrospective data review protocol and
a waiver of informed consent were approved by the in-
stitutional review board of MDACC for this study.
HLATyping
Intermediate- or high-resolution HLA typing at
HLA-A, -B, -C, -DRB1, and -DQB1 was performed
for all samples either prospectively or on archived
samples by polymerase chain reaction (PCR) amplifi-
cation and oligonucleotide hybridization using molec-
ular methods and commercial kits from Invitrogen
(Carlsbad, CA), ELPHA (Dreieich, Germany), and/
or One Lambda (Canoga Park, CA) that achieved in-
termediate resolution. The patients were also typed
for these loci by high-resolutionmethods (PCR ampli-
fication and nucleotide sequencing) using SEQR
Sequence Based Typing Kits (Abbott Park, IL). Addi-
tional high-resolution tests for selected loci were done
in the donors for whom an allele-level mismatch could
not be ruled out [16].Statistical Analysis
Time-to-event was assessed starting on the day of
transplantation. Actuarial overall survival (OS) and
progression-free survival (PFS) were estimated by the
method of Kaplan and Meier with death from any
cause, disease progression, and death in the absence
of disease progression considered the outcomes of
interest, respectively [17]. The incidence of disease
progression, NRM, and GVHD were estimated using
the cumulative incidence method to account for com-
peting events [18]. Death in the absence of disease
progression, disease progression, and death without
GVHD were considered competing events for the
respective outcomes. Comparison of outcomes was
performed by univariate analysis using the Cox pro-
portional hazards model [19]. Because of sample size
limitations, we could not perform multivariate analy-
ses to evaluate the independent effect of type of donor
on transplantation outcome. Instead, we performed
a matched analysis to adjust for the factors most com-
monly correlated with outcome, including diagnosis,
disease status at transplantation, intensity of the condi-
tioning regimen, and patient age (within a decade).
The matching was performed manually at a ratio of
1:1 for recipients of a related and MUD. If more
than 1match was available, the 1 with the closest trans-
plant date was selected. Statistical significance was
defined as P # .05. Analysis was performed using
STATA software: Release 9.0. (Stata Corp, College
Station, TX).RESULTS
Outcomes for Patients Treated with a 7/8 HLA
MRD
We initially evaluated outcomes in themismatched
related donor group based on 4 loci including high-
resolution typing at the HLA-C locus only. Specifi-
cally, we compared outcomes of patients treated
with related donors and 1-antigen/allele mismatch (or
7/8 MRD, n 5 49) with outcomes of patients who
received a 10/10MUD transplant (n5 318). In univar-
iate analyses, outcomes for patients who received 7/8
MRD transplants were worse at 3 years, with an OS
rate of 24% (95% confidence interval [CI] 12-38) and
a PFS rate of 22% (95% CI 11-36) compared with
45% (95% CI 38-51) and 42% (95% CI 36-48) for
the MUD group (hazard ratio [HR]OS 5 1.7; 95% CI
1.2-2.5; P 5 .05 and HRPFS5 1.8; 95% CI 1.2-2.6;
P5 .03).
Outcomes for Patients Treated with
9/10 HLA MRD
To further assess the impact of high-resolution
typing on outcomes, we performed a subset analysis
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ceived a transplant from a 9/10 MRD based on 5 loci
(including -DQB1) typing. Outcomes of these patients
were compared with outcomes of patients who had re-
ceived a MUD graft (n5 318), both in unmatched and
matched analyses. Only 24 of 28 9/10 MRD patients
could be matched and included in the comparison
with the MUD transplant patients based on age, dis-
ease status, conditioning regimen, and source of stem
cells. Characteristics and results of the matched and
unmatched analyses are presented in Tables 1 and 2.
Patient Characteristics
Unmatched analysis
Patient characteristics for the 9/10 MRD and
MUD groups were comparable except for a nonsignif-
icant younger age in the MRD group (47 years versus
53 years, P5 .08) and a significantly higher proportion
of patients who received antithymocyte globulin
(ATG) as part of the conditioning regimen in the
MUD group (96% versus 68%, P 5 .02).
The majority of patients in both the 9/10 MRD
(82%) and MUD (84%) groups had acute myeloid
leukemia/myelodysplastic syndrome with a similar
proportion of patients having active disease at the
time of transplantation (57% and 59%, respectively).
Two-thirds of patients in both the 9/10 MRD and
MUD groups had received ablative conditioning.
The median year of transplantation was also similar
(2004 for the 9/10 MRD group and 2006 for the
MUD group). A small proportion of patients in both
groups received pentostatin as part of a clinical trial
aimed at preventing acuteGVHD(aGVHD) (Table 1).
Matched analysis
Patients who received transplants from 9/10 MRD
and MUD were matched 1:1 for the characteristics
mentioned above. The only significant difference be-
tween the 2 groups was the use of ATG in the condi-
tioning regimen, as all patients in the unrelated
group had received ATG compared with 79% in the
related group (P\ .01) (Table 1).
Outcomes for 9/10 HLAMatched Related versus
10/10 MUD Transplants
Engraftment, NRM, aGVHD, and progression
Graft failure was more common in patients treated
from 1-allele mismatch related donors than from
MUD. The incidences of primary graft failure for
the 9/10 MRD group in the unmatched and matched
analyses were 7% and 8%, respectively, whereas
none of the MUD transplant recipients had a primary
(or secondary) graft failure (P 5 .02) (Table 2).
The incidence of NRMwas also higher in the 9/10
MRD than in the MUD group, with a 3-year cumula-tive incidence rate of 40% versus 26% in the un-
matched analysis (HR 5 1.9; 95% CI 1.0-3.6; P 5
.05) and 43% versus 25% in the matched analysis
(HR5 2.7; 95%CI 0.9-7.9; P5 .07; Table 2). The cu-
mulative incidence of grade II-IV aGVHD appeared
higher in MUD transplant recipients; however, this
did not reach statistical significance (P 5 .10) (Table
2). Because ATG is used primarily to prevent aGVHD,
and because all patients who had graft rejection in the
9/10 MRD group received ATG as did the great ma-
jority of the patients in the 10/10 MUD group, differ-
ences in ATG use between the 9/10 MRD and MUD
groups noted in this study are unlikely to be responsi-
ble for worse outcomes seen with the use of 9/10MUD
grafts. Moreover, differences between the 2 groups
could not be explained by differences in conditioning
as 181/318 patients (57%) received myeloablative flu-
darabine and busulfan (FluBu) and 98/318 (31%) re-
ceived fludarabine and melphalan (FluMel) in the
MUD groups compared with 14/28 (50%) FluBu
and 7/28 (25%) FluMel in the 9/10 MRD group (P
5 .50 for both). A nonsignificant higher rate of disease
progression between the 9/10 MRD compared with
the MUD group was noted in the matched analysis
(P 5 .5) (Table 2).
Survival and causes of death
After a median follow-up of 56 months (range:
6-143) in recipients of 9/10 MRD grafts and 22
months (range: 2-93 months) in recipients of MUD
grafts, a total of 24 deaths had occurred in the first
group and 154 deaths in the second group. The major-
ity of these deaths occurred within 2 years after trans-
plantation, including 79% in the related group and
96% in the MUD group. Significantly better 3-year
OS and PFS were found in the MUD than in the 9/
10 MRD transplant groups in the unmatched analysis.
Better OS in the MUD group was also noted in the
matched analysis at 3 years; however, differences in
PFS did not reach statistical significance, likely be-
cause differences between the 2 groups were related
to NRM rather than relapse (Table 2). In the un-
matched analysis, median survival was 6 months for
the 9/10 MRD group versus 18 months for the 10/10
MUD group. Three-year OS rates were 19% and
45% in 9/10 MRD and MUD groups, respectively
(HR 5 1.8; 95% CI 1.2-2.9; P 5 .007). Similarly,
3-year PFS rates were more favorable in the MUD
group, with 42% versus 19% (HR 5 1.8; 95% CI
1.2-2.9; P 5 .006) in the unmatched analysis.
Because all but 1 of the MUD transplants included
in this study (n5 317, 99%)were performed after 2001
compared with only 20 out of 28 (71%) of 9/10 MRD
transplants, we compared outcomes for the 2 groups
transplanted after this year. Our data showed signifi-
cant differences in survival, OS was 44% (38-51) in
the MUD versus 22% (6-42) in the 9/10 MRD group
Table 1. Patients’ Characteristics
Unmatched Analysis Matched Analysis
9/10 Related (n 5 28) 10/10 MUD (n 5 318) 9/10 Related (n 5 24) 10/10 MUD (n 5 24)
Age
Median (range) 47 (12-69) 53 (13-75) 52 (14-69) 51 (23-68)
P* .08
Diagnosis (number, %)
AML/MDS 23 (82%) 266 (84%) 21 (88%) 22 (92%)
CML/MPD 5 (18%) 52 (16%) 3 (12)% 2 (8%)
P* .5
Disease status (number, %)
Active disease 16 (57%) 187 (59%) 14 (58%) 14 (58%)
First relapse refractory 4 4
First relapse untreated 5 5
Primary induction failure 4 4
Untreated 1 1
Remission 12 (43%) 131 (41%) 10 (42%) 10 (42%)
First complete remission 4 4
Second complete remission 4 4
First chronic phase 1 1
Second chronic phase 1 1
P* .90
Conditioning (number, %)
Ablative 21 (75%) 201 (63%) 17 (71%) 17 (71%)
RIC 7 (25%) 117 (37%) 7 (29%) 7 (29%)
P* .20
Stem cell source (number, %)
Bone marrow 20 (70%) 185 (58%) 17 (71%) 17 (71%)
Peripheral blood 8 (30%) 133 (42%) 7 (29%) 7 (29%)
P* .20
ATG (number, %)
Yes 19 (68%) 304 (96%) 19 (79%) 24 (100%)
No 9 (32%) 14 (4%) 9 (32%) 0
P* .02 <.01
Pentostatin (number, %)
Yes 3 (11%) 45 (14%) 3 (12%) 3 (12%)
No 25 (89%) 273 (86%) 21 (88%) 21 (88%)
P* .40
Median transplant year (range) 2004 (1996-2009) 2006 (2001-2009) 2004 (1999-2009) 2005 (2001-2009)
P .30
MUD indicates matched unrelated donor; RIC, reduced-intensity conditioning; ATG, antithymocyte globulin; AML, acute myeloid leukemia; MDS,
myelodysplastic syndromes; CML, chronic myeloid leukemial; MPD, myeloproliferative diseases.
*P is for comparison of patients characteristics of the 9/10 matched related versus 10/10 matched unrelated patients.
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(36-49) versus 22% (7-43) (HR 5 1.7; 95% CI 1.03-
2.9; P 5 .04) for patients treated after the year 2001.
Causes of death in the study patients are presented
in Table 2. In the unmatched analysis, 21% of the pa-
tients had graft failure as their primary cause of death
in the MRD group versus 3% in the MUD group.
This difference was even greater in thematched analysis
(23% versus 0%, respectively). Taken together, these
results suggest that transplant outcomes for patients
treated with a 9/10 MRD are worse than those for
patients treated with 10/10 MUD transplants.
However, the poorer survival in the 9/10 MRD
group could be because 24 of 28 patients in this group
had class I mismatches. For a subset analysis, we com-
pared the 24 patients with class I mismatches and 11
patients with class II mismatches (4 patients with
a single class II mismatch at -DRB1 and 7 patients
with both -DRB1 and -DQB1 mismatches). Median
OS for class I and class II allele mismatches was 5
months and 44 months, and actuarial 2-year OS rateswere 29% versus 54% (P 5 .30). Compared with the
10/10 MUD group, patients treated with class II mis-
matches (HLA-DRB1 6 -DQB1) in the MRD group
had similar outcomes, with an actuarial PFS at 2 years
of 45% in the MRD group and 46% in MUD group
(P 5 .80), and no differences in incidence of aGVHD,
relapse, or NRM. However, outcomes for 9/10 MRD
transplant patients with class I mismatches (n 5 24)
were significantly worse than outcomes in those with
MUD transplants (Figure 1). In the unmatched analy-
sis, the actuarial OS rate at 2 years was 27% for the 9/
10 MRD group and 48% for the MUD transplant
group (HR5 1.9; 95%CI 1.1-3.1; P5 .01).When ad-
justed for disease status at transplant, the difference
remained statistically significant (P 5 .03).DISCUSSION
HLA typing has improved over time, leading to
improved outcomes for patients treated with
Table 2. Treatment Outcomes for 346 Patients Treated from Matched Unrelated (n 5 318) and 9/10 Matched Related (n 5 28)
Donors
Outcomes at 3 Years Posttransplant
Unmatched Analysis Matched Analysis
9/10 Related (n 5 28) 10/10 MUD (n 5 318) 9/10 Related (n 5 24) 10/10 MUD (n 5 24)
Median follow-up in survivors (months, range) 56 (6-143) 22 (2-93) 32 (6-59) 49 (10-93)
Graft failure
Primary 2 (7%) 0 2 (8%) 0
Secondary 4 (14%) 0 4 (17%) 0
P† .02
Overall survival
Median (months) 6 18 6 18
OS (95% CI) 19% (7-35) 45% (38-51) 13% (3-30) 38% (17-59)
Hazard ratio 1.8 Reference 2.1 Reference
95% CI (1.2-2.9) (1.0-4.2)
P† .007 .04
Progression-free survival
Median (months) 4 15 4 7
PFS† (95% CI) 19% (7-36) 42% (36-48) 13% (3-31) 31% (14-51)
Hazard ratio 1.8 Reference 1.6 Reference
95% CI (1.2-2.9) (0.85-3.1)
P† .006 .10
Progression
Cumulative incidence (95% CI) 40% (25-64) 25% (20-30) 43% (27-69) 39% (23-65)
Hazard ratio 2.1 Reference 1.4 Reference
95% CI (1.1-3.9) (0.5-3.4)
P† .02 .50
Nonrelapse mortality
Cumulative incidence (95% CI) 40% (25-63) 26% (21-32) 43% (27-68) 25% (13-50)
Hazard ratio 1.9 Reference 2.7 Reference
95% CI (1.0-3.6) (0.9-7.9)
P† .05 .07
Grade II-IV acute GVHD
100 days cumulative incidence 27%* (15-52) 38% (32-44) 23%* (10-49) 42% (26-67)
Hazard ratio 0.7 Reference 0.5 Reference
95% CI (0.3-2.5) (0.2-1.5)
P† .40 .10
Causes of death n 5 24 n 5 154 n 5 22 n 5 13
Graft failure 5 (21%) 4 (3%) 5 (23%) 0 (0%)
Infection 3 (12.5%) 31 (20%) 2 (9%) 2 (15%)
Relapse 9 (37.5%) 76 (49%) 9 (41%) 7 (54%)
GVHD 2 (8.3%) 23 (15%) 2 (9%) 3 (23%)
Organ failure 2 (8.3%) 13 (8.5%) 1 (4.5%) 1 (8%)
Other 3 (12.5%) 7 (4.5%) 3 (13.6%) —
MUD indicates matched unrelated donor; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; GVHD, graft-
versus-host disease.
*Excluding patients with primary graft failure.
†P is for comparison of outcomes between the 9/10 matched related versus 10/10 matched unrelated patients.
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Here, we compared the outcomes of patients treated
with 9/10 MRD grafts having a single mismatched an-
tigen/allele with outcomes of those treated with MUD
grafts. We have found that patients treated with mis-
matched related grafts fared significantly worse than
those treated with MUD transplants.
HLA 1-antigen/allele mismatch related donors are
relatively uncommon, and data from a small number of
studies have shown similar outcomes between 7/8
MRD and 8/8 MUD groups [13-15]. Many centers
have preferentially used a 9/10 related donor for
transplantation because of the immediate availability
and because the potentially larger number of minor
antigen mismatches in unrelated individuals could
negatively influence outcomes [20,21].
Previous studies have identified a higher risk of
graft rejection with increasing numbers of HLA mis-matches [2,9,14,22]. Leung et al. [23] suggested that
a single mismatch in class I antigens (HLA-A or -B)
may not be better tolerated than a disparity at HLA-
DRB1. Morishima and colleagues [24] also reported
that, after assessment with high-resolution HLA typ-
ing, disparities at HLA-A and -B are associated with
more graft failure, GVHD, and worse survival. In un-
related donor setting, Flomenberg et al. [25] found
that HLA mismatches at HLA-A, -B, -C and -DRB1
adversely affected outcomes, whereas mismatches at
-DQB1 and -DPB1 did not.
Our findings suggest that differences in outcomes
can be explained by the higher rates of NRM in the
mismatched related group, predominately because of
a higher incidence of graft rejection, because GVHD
rates were not significantly different. In order to ex-
plain differences in graft rejection between the 9/10
MRD patients that engrafted and those that did not,
Figure 1. Difference in 3-year OS between matched unrelated donor
(n5 318) and 1-antigen/allele mismatch related donor transplants (n5
28) at M.D. Anderson Cancer Center by high-resolution HLA typing at
HLA-A, -B, -C, -DRB1, and -DQB1 (P 5 .04).
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tially associated with graft rejection. No significant
differences in the use of ATG or in ABO blood group
mismatch were found between these 2 groups. In addi-
tion, 2 of the 6 patients who had primary graft failure
were tested for donor-specific anti-HLA antibodies,
and they were negative [26].
Contrary to our findings, other investigators have
shown equivalent outcomes between 7/8 MRD donors
and 8/8 MUD grafts. This difference may result from
the fact that our study containedmore patients with class
I mismatches, which appear to have higher NRM and
worse prognosis. Conflicting data exist regarding
-DRB1 mismatches. Some studies have suggested
that outcomes are worse with suchmismatches, whereas
other studies did not confirm this finding [2,9,10,14,
23-25]. Our results suggest that mismatches at the
-DRB1 locus are better tolerated than single class I
mismatches. Furthermore, similarly to data from
MUD setting, we have found that -DQB1 mismatches
are better tolerated and not associated with worse
outcomes when this mismatch is added to either a class
I or -DRB1 mismatch in the 9/10 MRD patients [10].
Limitations of the present study include its retro-
spective nature and the relatively small number of
patients. However, we identified a marked difference
in outcomes between 1-antigen/allele MRD and 10/10
MUD transplants. Future studies will need to evaluate
outcomes for patients with class I versus class II 1-
antigen/allele mismatches using HLA typing at 5 loci,
because our results suggest that patients with class II
mismatches have outcomes comparable with outcomes
of those having 10/10MUD transplants and fare signif-
icantly better than those with class I mismatches.
In conclusion, our results suggest that, using the
standard approach, outcomes are worse for recipients
of 1-antigen/allele mismatch related donor hemato-
poietic stem cell transplants, and a 10/10MUD, shouldbe the preferred choice for patients who lack a
matched-related donor. However, newer approaches
to haploidentical transplantation using high-dose post-
transplant cyclophosphamide have improved engraft-
ment, decreased NRM, and improved outcomes,
suggesting that patients receiving transplants from
a 9/10 MRD, at least with a class I mismatch, should
be treated on protocols similar to haploidentical
transplants [27].ACKNOWLEDGMENTS
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